BEIJING,March 3,2025-- Mushrooms cultivated by an agricultural technology company based in Shizhong District of Zaozhuang City,east China\'s Shandong Province,have entered harvest season recently.
BARCELONA,Spain,March 3,2025-- TCL,a pioneer in display across feature-rich smartphones,tablets,and connected devices,today announced the launch of the TCL NXTPAPER 11 Plus Tablet at Mobile World Cong
DOHA,Qatar,Feb. 17,2025--Following a series of successful brand launch events across the Middle East,SOUEAST is set to introduce a large-scale light show event under the theme "EASE YOUR LIFE&quo
JARKATA,Indonesia,Feb. 14,2025--The ASEAN Foundation,supported by Google.org,successfully hosted the 1st Regional Policy Convening of AI Ready ASEAN at ASEAN Headquarters/ASEAN Secretariat,Jakarta,on
GUANGZHOU,China,Feb. 14,2025-- News report from GDToday. A photo exhibition titled "Nihao,China! See You in Guangdong" was held in Orange County,California,from January 23 to February 12,sho
WUHU,China,Feb. 14,2025--The T1 series,a new member ofJETOUR brand with a lite off-road shape artfully blending sportiness and toughness,has been awarded the 2024 Red Dot Design Concept Award. By winn
HANGZHOU,China,Feb. 14,2025-- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK),the world\'s leading premium new energy vehicle group,today a
SINGAPORE,Feb. 14,2025-- ATxEnterprise (ATxE) 2025,a flagship event of Asia Tech x Singapore (ATxSG),returns for its fifth year,providing a strategic platform for enterprises,governments,and technolo
BEIJING,Feb. 14,2025--A news report by China.org.cn on China\'s AI application:  
SHENZHEN,China,Feb. 14,2025-- Kexing Biopharm Co.,Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05,Human Interferon α1b Inhalation Solution,
SEOUL,South Korea,Feb. 13,2025-- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement w
XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).
© OfficialAffairs
